Semax comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-25. Numbers and descriptions here follow the published literature rather than marketing material.
Quality documentation for research-grade peptide usually includes a certificate of analysis stating purity, identity, and residual counterion content. Batch-to-batch variation in purity and salt form is a recognized issue, and comparisons across suppliers require attention to the exact counterion, for example acetate versus trifluoroacetate. Sequence verification by tandem mass spectrometry provides stronger evidence than a single mass measurement. For any study reporting biological results, the analytical method and the measured purity should be stated explicitly. Independent verification of supplier claims is considered good practice.
Semax is supplied as a lyophilized powder that appears white to off-white. It dissolves readily in water, phosphate-buffered saline, and other aqueous media, which simplifies preparation of working solutions for laboratory use. The nasal products registered in Russia are dilute aqueous solutions, typically around 0.1 percent peptide by weight. Organic solvents are rarely necessary and can complicate handling. Because the peptide is hygroscopic, weighing should be performed quickly and with minimal exposure to ambient humidity.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
| Property | Value | Notes |
|---|---|---|
| Typical purity | ≥95% by HPLC | Research-grade material |
| Detection wavelength | 214 nm | Peptide bond absorbance |
| Reconstitution medium | Sterile water or saline | Prepare fresh or aliquot immediately |
| Storage (solution) | -80 °C, single-use aliquots | Avoid repeated freeze-thaw cycles |
| Common salt form | Acetate or trifluoroacetate | Affects mass and solubility |
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.
Identity and purity are confirmed with reversed-phase high-performance liquid chromatography, typically monitored at 214 nanometres where the peptide bond absorbs. Mass spectrometry, either electrospray or MALDI-TOF, verifies molecular mass against the theoretical value and detects truncation or adduct formation. Amino acid analysis and peptide mapping provide additional confirmation when required. The most frequently reported impurities are deletion sequences from incomplete coupling, methionine sulfoxide from oxidation, and dimeric species formed through non-covalent aggregation. Impurity profiles depend strongly on the synthesis and purification route chosen by the producer.
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
Verification of a supplied batch generally combines a certificate of analysis with independent testing, because certificates are self-reported documents. A typical package includes a chromatographic trace, a mass spectrum, and a stated water or counter-ion content. Batch-to-batch consistency matters more than a single purity figure when results are compared across experiments. No single mandatory standard governs research-grade peptide release, so laboratories are expected to define their own acceptance criteria. Residual trifluoroacetate from purification is a frequently overlooked counter-ion.
Lyophilized material is chemically stable for extended periods when kept dry, cold, and protected from light. The powder is hygroscopic, so vials should be warmed to room temperature before opening to reduce condensation on the contents. Once dissolved, the peptide is far less stable because peptide bonds are susceptible to hydrolysis and the methionine residue can oxidize. Solutions are typically aliquoted and held at 2-8 °C for short intervals or frozen for longer ones, and repeated freeze-thaw cycles should be avoided.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
==== Adherence ==== Poor compliance with medications and follow-up visits are a major reason for treatment failure and disease progression in glaucoma patients. Poor adherence could lead to increased complication rates, thus increasing the need for non-pharmacological interventions, including surgery. Patient education and communication must be ongoing to sustain successful treatment plans for this lifelong disease with no early symptoms.
=== Examining what occurs at the cellular level of NL. === Tissue Architecture in NL Lesions A lesion is a tissue that has been altered or injured. They can occur as wounds or, in the case of progressive NL, ulcers. The tissue architecture of NL is characterized by degeneration of collagen in the dermis and subcutaneous layers. The lesions exhibit granulomatous inflammation, palisading granulomas, and thickened blood vessels. Palisading granulomas are significant because they show an immune cell ring around degenerated tissue, commonly seen in autoimmune and chronic inflammatory diseases. Thickened blood vessels occur due to an accumulation of immune cells. Together, all these structural features indicate NL as a chronic, inflammatory response. Fibroblasts and endothelial cells are malfunctioning, and there is an imbalance in tissue homeostasis. Fibroblast and collagen remodeling Fibroblasts contribute to the formation of connective tissue, collagen, and elastin. Failure in fibroblasts causes skin to atrophy and degenerate. Increased uptake of GLUT-1 (a glucose transporter) is observed in NL cases. When up-regulated: glycolysis, oxidative stress, and fibroblast proliferation all increase. Despite the metabolic increase, fibroblasts in NL dysfunction. This suggests that in NL tissue decay and dysfunction are linked to both structural and immunological tissue components. The tissue is observed to have increased GLUT-1 and decreased pro-collagen mRNA. A predominance of Type 1 collagen is observed in PL.
=== Molecular mimicry === Some infectious agents, like Campylobacter jejuni, bear antigens that resemble, but are not identical to, the body's self-molecules. This phenomenon, known as molecular mimicry, can lead to cross-reactivity, where the immune response to such infections inadvertently results in the production of antibodies that also react with self-antigens. An example of this is Guillain–Barré syndrome, in which antibodies generated in response to a C. jejuni infection also react with the gangliosides in the myelin sheath of peripheral nerve axons.
==== Elastin ==== Elastins, in contrast to collagens, give elasticity to tissues, allowing them to stretch when needed and then return to their original state. This is useful in blood vessels, the lungs, in skin, and the ligamentum nuchae, and these tissues contain high amounts of elastins. Elastins are synthesized by fibroblasts and smooth muscle cells. Elastins are highly insoluble, and tropoelastins are secreted inside a chaperone molecule, which releases the precursor molecule upon contact with a fiber of mature elastin. Tropoelastins are then deaminated to become incorporated into the elastin strand. Disorders such as cutis laxa and Williams syndrome are associated with deficient or absent elastin fibers in the ECM.
=== Chemical === Powdered thorium metal is pyrophoric: it ignites spontaneously in air. In 1964, the United States Department of the Interior listed thorium as "severe" on a table entitled "Ignition and explosibility of metal powders". Its ignition temperature was given as 270 °C (520 °F) for dust clouds and 280 °C (535 °F) for layers. Its minimum explosive concentration was listed as 0.075 oz/cu ft (0.075 kg/m3); the minimum igniting energy for (non-submicron) dust was listed as 5 mJ. In 1956, the Sylvania Electric Products explosion occurred during reprocessing and burning of thorium sludge in New York City, United States. Nine people were injured; one died of complications caused by third-degree burns.
Sources: en.wikipedia.org
Amino Acid + ATP + tRNA → Aminoacyl-tRNA + AMP + PPi The net reaction is energetically favorable only because the pyrophosphate (PPi) is later hydrolyzed. The hydrolysis of pyrophosphate to two molecules of inorganic phosphate (Pi) reaction is highly energetically favorable and drives the other two reactions. Together, these highly exergonic reactions take place inside the aminoacyl-tRNA synthetase specific for that amino acid.
(2026) study the fossil record of Pleistocene brown bears from Portugal, reporting evidence of presence of robust individuals with features convergent with cave bears and some of the largest brown bears in the fossil record reported to date, as well as evidence of size reduction during the Holocene that might have been linked to human pressure and habitat destruction. Evidence from the study of mandibles of Pleistocene and Holocene browns bears, indicative of differences of masticatory adaptations of bears from warm and cold areas regardless of their geological age, is presented by van Heteren & Villalba de Alvarado (2026). Johnson et al. (2026) report the recovery of ancient DNA from the early Holocene glacial lake sediments in northern Sweden representing the oldest record of brown bear in the region reported to date, and report evidence of affinities of the studied individual with the southern population of Scandinavian brown bears, possibly indicating that the individual migrated northward from its birthplace. Evidence of a predominantly herbivorous diet of early Holocene brown bears from the Hattab II and Kehf el-Hammar sites (Morocco) is presented by Iken et al. (2026). Description of new fossil material of Trochotherium cyamoides from La Grive-Saint-Alban (France) and Kleineisenbach (Germany) and a study on the anatomy and affinities of members of this species is published by Sánchez-Hernández et al. (2026), who interpret T. cyamoides as a member of the stem group of Mephitidae that might have fed on terrestrial gastropods.
== Military career == After graduating from the Military Academy, al-Burhan worked in Khartoum, as part of the Sudanese army, and participated in the fighting fronts in the Darfur war and in the Second Sudanese Civil War in South Sudan and other regions. He was regional commander in Darfur. He later traveled to Egypt and then to Jordan to receive training courses in his military field until in 2018 he was appointed commander of the ground forces of the army. Al-Burhan held several positions throughout his career as he began as a soldier with the Border Guard Forces and later became commander of this force before becoming Deputy Chief of Staff of the Ground Forces Operations and then Chief of Staff of the Sudanese Army in February 2018 before he served as Inspector General of the Army for a period of time. By 26 February 2019, during the massive protests that swept the country and demanded the fall of Omar al-Bashir's regime, al-Burhan was elevated to the rank of lieutenant general.
To maintain effectiveness, platelet-mimicking particles have to be engineered to remain stable in the bloodstream long enough to reach tumor sites without being rapidly cleared. Simultaneously, they must also be designed to degrade safely after successful drug delivery to tumor sites to avoid triggering adverse immune reactions. Regulatory issues and mass production also become problematic because safety and efficacy evaluation of the synthetic platelet requires extensive preclinical and clinical testing. Overcoming these deficiencies will advance their integration into standard oncological treatments.
=== Environmental exposure === Exposure to fungal species that secrete gliotoxin is common because airborne Aspergillus fungal spores are ubiquitous in many environments. Regular environmental exposure does not typically cause illness, but can cause serious infections in immunosuppressed individuals or those with chronic respiratory illnesses. Infection caused by Aspergillus fungus is called aspergillosis. There are many types of aspergillosis, but infections typically affect the lungs or the sinuses. Gliotoxin is hypothesized to be an important virulence factor in Aspergillus fumigatus. Experiments have demonstrated that gliotoxin is isolated in the highest concentrations from Aspergillus fumigatus in comparison to other Aspergillus species. This species of fungi is the most common cause of aspergillosis in humans. Gliotoxin is also the only toxin that has been isolated from the sera of patients with invasive aspergillosis. These results suggest a link between gliotoxin secretion and fungal pathogenicity. While not enough data exists to definitively tie chronic gliotoxin exposure to the development of cancer, chronic exposure to other immunosuppressive agents has been linked to the development of lymphomas and mammary tumors. Individuals taking immunosuppressive medications or with previous or current exposure to chemotherapy radiation are at higher risk for the development of these tumors.
Sources: en.wikipedia.org
Solid peptide is best kept frozen at about minus 20 degrees Celsius in a sealed container with desiccant. It should be allowed to reach room temperature before opening to prevent condensation. Repeated warming and cooling of the same vial is discouraged.
Reversed-phase liquid chromatography establishes purity, while mass spectrometry confirms molecular mass. The two techniques are normally used together. Retention time alone is not sufficient evidence of identity.
Different counterions change the mass per unit of peptide and can shift chromatographic behavior. Two samples of equal stated purity may therefore not be directly comparable. Reports should specify the counterion whenever quantitative comparisons are made.
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.